PMV Pharmaceuticals Files Definitive Proxy Statement
Ticker: PMVP · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1699382
| Field | Detail |
|---|---|
| Company | Pmv Pharmaceuticals, Inc. (PMVP) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, sec-filing
TL;DR
PMV Pharma filed its proxy statement for the June 5th meeting. Shareholders vote soon.
AI Summary
PMV Pharmaceuticals, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting on June 5, 2025. The filing, under the 1934 Securities Exchange Act, concerns the solicitation of proxies for the meeting. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals to be voted on, which can impact the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial information or strategic changes.
Key Numbers
- 20250605 — Annual Meeting Date (Shareholders will vote on proposals at this meeting.)
- 20250425 — Filing Date (The definitive proxy statement was filed on this date.)
Key Players & Entities
- PMV Pharmaceuticals, Inc. (company) — Registrant
- 0001699382 (company) — Central Index Key
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 1934 Act (company) — SEC Act
- 001-39539 (company) — SEC File Number
- 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON, NJ 08540 (company) — Business Address
- (609) 642-6670 (company) — Business Phone
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon.
When is the annual meeting of PMV Pharmaceuticals, Inc. scheduled?
The annual meeting of PMV Pharmaceuticals, Inc. is scheduled for June 5, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 25, 2025.
What is the company's fiscal year end?
PMV Pharmaceuticals, Inc.'s fiscal year ends on December 31.
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding PMV Pharmaceuticals, Inc. (PMVP).